← Back to Search

GE180 PET Scan for Alzheimer's Disease

Phase 2

Waitlist Available

Led By Aaron R Ritter, MD

Research Sponsored by Aaron Ritter, MD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline (pre-scan)

Awards & highlights

Study Summary

This trial will use GE180, a newly developed PET ligand, to study regional and global inflammation in the brains of patients with Alzheimer's disease and Parkinson's disease.

Eligible Conditions

Alzheimer's Disease
Parkinson's Disease
Inflammation

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline (pre-scan)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline (pre-scan)

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (pre-scan) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Cingulate GE180 Standardized Uptake Value Ratio (SUVR)

Dementia Rating Score

Executive Function Composite Score (Z-score)

+8 more

Trial Design

4Treatment groups

Experimental Treatment

Group I: Parkinson's DiseaseExperimental Treatment1 Intervention

Parkinson's Disease GE180 PET Scan

Group II: Mild Cognitive ImpairmentExperimental Treatment1 Intervention

Mild Cognitive Impairment GE180 PET Scan

Group III: ControlExperimental Treatment1 Intervention

Control Group GE180 PET Scan

Group IV: Alzheimer's DiseaseExperimental Treatment1 Intervention

Alzheimer's Disease GE180 PET Scan

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Aaron Ritter, MDLead Sponsor

Aaron R Ritter, MDPrincipal InvestigatorThe Cleveland Clinic

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this clinical trial willing to enroll patients that are over 45 years old?

"The age limit to qualify for this trial is 55 years old. However, the maximum age a candidate can be is 90 years old."

Answered by AI

What are some risks associated with GE180 PET Scans?

"The GE180 PET Scan is a Phase 2 trial, which means that while there is some evidence supporting its safety, there is no such data for efficacy. Our team at Power estimates its safety to be a 2 on a scale from 1 to 3."

Answered by AI

Are we still enrolling patients for this research project?

"The latest information available on clinicaltrials.gov suggests that this trial is not currently looking for new participants. This particular study was first posted on December 13th, 2018 and was last updated on May 12th, 2022. However, there are 1438 other trials actively recruiting patients right now."

Answered by AI

To whom is this study open for enrollment?

"The ideal candidate for this medical trial is aged 55 to 90, has inflammation, and meets the following additional requirements: currently enrolled in CNTN, available study partners, willing and able to participate in follow-up appointments."

Answered by AI

Recent research and studies

Neural PlasticityJournal

Microglia: An Active Player in the Regulation of Synaptic Activity

Ji, Kyungmin, Jeremy Miyauchi, and Stella E. Tsirka. 2013. “Microglia: An Active Player in the Regulation of Synaptic Activity”. Neural Plasticity. Hindawi Limited. doi:10.1155/2013/627325.

BrainJournal

Reactive Microglia Drive Tau Pathology and Contribute to the Spreading of Pathological Tau in the Brain

Maphis, Nicole, Guixiang Xu, Olga N. Kokiko-Cochran, Shanya Jiang, Astrid Cardona, Richard M. Ransohoff, Bruce T. Lamb, and Kiran Bhaskar. 2015. “Reactive Microglia Drive Tau Pathology and Contribute to the Spreading of Pathological Tau in the Brain”. Brain. Oxford University Press (OUP). doi:10.1093/brain/awv081.

Brain ResearchJournal

Peripheral Type Benzodiazepine Binding Sites Are a Sensitive Indirect Index of Neuronal Damage

Benavides, Jesus, Dominique Fage, Christopher Carter, and Bernard Scatton. 1987. “Peripheral Type Benzodiazepine Binding Sites Are a Sensitive Indirect Index of Neuronal Damage”. Brain Research. Elsevier BV. doi:10.1016/0006-8993(87)91287-x.

Alzheimer's & DementiaJournal